Verition Fund Management’s Cidara Therapeutics CDTX Stock Holding History

Verition Fund Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-217,900	Closed	-$48.1M	–	2452
2025 Q4	$48.1M	Buy	+217,900	New	+$35.2M	0.19%	68

Verition Fund Management's CDTX Position: Q1 2026 in Review

Verition Fund Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 210,329 shares — an estimated $46.5M sold.

Verition Fund Management first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $46.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Verition Fund Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Verition Fund Management sold 210,329 Cidara Therapeutics shares in Q1 2026, an estimated $46.5M.
Verition Fund Management first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Verition Fund Management's Cidara Therapeutics position peaked at $46.5M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.